Book an appointment with Boardroom Media using SetMore
Connect with us

MYLAN - 2018 Investor Day

Company estimates that 75% of its free cash flows are durable...."We've been able to build tremendous diversity around our commercial, operational and scientific platforms," said Mylan CEO Heather Bresch.


Investor Day Highlights Durability of Mylan's Global Platform

Management details progress on complex scientific programs and commercial diversification; reaffirms 2018 guidance

Company is built to last and positioned for growth

HERTFORDSHIRE, England and PITTSBURGH, April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today will host an Investor Day, which focuses on the global powerhouse's differentiation and durability, including its longtime mission to expand access to medicine, commitment to complex scientific programs and commercial diversification, and significant financial flexibility. Additionally, the presentation highlights recently announced opportunities, including:

Mylan's acquisition of the global marketing rights to a once-monthly Glatiramer Acetate product through a partnership with Mapi Pharma;
a partnership with Fujifilm Kyowa Kirin Biologics to commercialize a biosimilar to Humira® (adalimumab) in Europe (link to announcement);
and Mylan's acquisition of the global development and marketing rights from Prayog Labs for a new, fast-acting formulation of Meloxicam, a non-opioid pain management option.
Mylan CEO Heather Bresch commented: "For nearly 60 years, Mylan has remained true to its core purpose of providing access to medicine. To expand access, we've built tremendous diversity into our commercial, operational and scientific platforms. The result is a durable business model that delivers consistent and reliable results. Today, for example, we estimate that 75% of the cash flows that Mylan generates are stable and durable. We look forward to continuing to engage our many stakeholders about Mylan's unique profile."

Mylan President Rajiv Malik commented: "We are uniquely positioned to maximize opportunities for continued growth and commercial differentiation in the global markets we serve. In parallel, the scientific expertise we have amassed over the past decade fuels our ability to continue driving the company's commercial success. To this end, in 2018 we have dedicated more than half of our R&D investments to complex product development. Complex products represent about 70% of Mylan's overall pipeline value, based on IQVIA brand values. These investments continue to build on our proven ability to develop and commercialize difficult-to-manufacture products for patients."


LINKS

INVESTOR RELATIONS

WEBCAST

GOOGLE FINANCE






COMMENTS

THE STREET:  Mylan officials acknowledged that making a Botox biosimilar is a challenging task, but expressed confidence that they can get it done.
https://www.thestreet.com/markets/mylan-spotlights-diversification-at-investor-day-14553013

PRNEWSWIRE: Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today will host an Investor Day, which focuses on the global powerhouse's differentiation and durability, including its longtime mission to expand access to medicine, commitment to complex scientific programs and commercial diversification, and significant financial flexibility.
https://www.prnewswire.com/news-releases/investor-day-highlights-durability-of-mylans-global-platform-300628286.html
Advertisement